To identify the best first-line therapy for advanced lung cancer in patients with performance status 2 without a targetable mutation or with an unknown mutation status.
This is a protocol.
To identify the best first-line therapy for advanced lung cancer in patients with performance status 2 without a targetable mutation or with an unknown mutation status.
This is a protocol.